Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study

Exclusion Criteria

• •Brain metastases
• •Ocular primitive melanoma
• •Treatment of metastatic melanoma by more than two lines (chemotherapy , immunotherapy, targeted therapy or radiotherapy) or within 4 weeks before the inclusion
• •Treatment with ipilimumab within 8 weeks before the inclusion
• •Known allergy to albumin
• •Contraindication to the use of vasopressors
• •Positive viral serology for HIV 1/2 , Ag p24 , HTLV 1/2, hepatitis B or C, or syphilis
• •Women who are pregnant, nursing or refusing to use contraceptives, women with no negative pregnancy test at baseline
• •Presence of a second active cancer (with the exception of cervical cancer in situ or skin cancer other than melanoma)
• •History of event or current event of a progressive or non-stabilized severe heart disease (congestive heart failure, coronary artery disease, uncontrolled hypertension, serious arrhythmias or ECG signs of previous myocardial infarction)
• •Uncontrolled thyroid dysfunction
• •Any serious acute or chronic illness (active infection requiring antibiotics, bleeding disorders or other condition requiring concomitant treatment not allowed in this study)
• •History of chronic autoimmune disease (Addison's disease, multiple sclerosis, Graves' disease, rheumatoid arthritis, systemic lupus erythematosus, ... ) with the exception of patients with active vitiligo or a history of vitiligo
• •History of uveitis and retinopathy associated with melanoma
• •Adults under a legal protection regime (guardianship, trusteeship, "sauvegarde de justice")